Literature DB >> 11772955

Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation.

J N Primrose1.   

Abstract

The liver is the most common site of metastases from colorectal cancer. There has therefore been growing interest in how liver metastases may be ablated. The most common techniques for ablation of liver metastases are surgical resection, cryotherapy, and increasingly in recent years, radiofrequency ablation.

Entities:  

Mesh：

Year:  2002        PMID： 11772955      PMCID： PMC1773068          DOI： 10.1136/gut.50.1.1

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  40 in total

1.  Liver anatomy: portal (and suprahepatic) or biliary segmentation.

Authors:  C Couinaud
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

Review 2.  Interstitial laser thermotherapy in the treatment of colorectal liver metastases.

Authors:  V Muralidharan; C Christophi
Journal:  J Surg Oncol       Date:  2001-01       Impact factor: 3.454

3.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 4.  Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies.

Authors:  C Rust; G J Gores
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

5.  Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm.

Authors:  A J Bilchik; T F Wood; D Allegra; G J Tsioulias; M Chung; D M Rose; K P Ramming; D L Morton
Journal:  Arch Surg       Date:  2000-06

Review 6.  Current treatment for colorectal cancer metastatic to the liver.

Authors:  M Cromheecke; K P de Jong; H J Hoekstra
Journal:  Eur J Surg Oncol       Date:  1999-10       Impact factor: 4.424

7.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

8.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.

Authors:  P C Simmonds
Journal:  BMJ       Date:  2000-09-02

9.  Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy.

Authors:  D Elias; A Goharin; A El Otmany; J Taieb; P Duvillard; P Lasser; T de Baere
Journal:  Eur J Surg Oncol       Date:  2000-12       Impact factor: 4.424

10.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544
View more
  23 in total

Review 1.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

Review 2.  Colorectal hepatic metastasis: Evolving therapies.

Authors:  Francisco Igor B Macedo; Tafadzwa Makarawo
Journal:  World J Hepatol       Date:  2014-07-27

3.  Experimental study on the feasibility and safety of radiofrequency ablation for secondary splenomagely and hypersplenism.

Authors:  Quan-Da Liu; Kuan-Sheng Ma; Zhen-Ping He; Jun Ding; Xue-Quan Huang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

4.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 5.  [Oligometastasized stage IV colorectal cancer : Surgical resection and local ablative procedures].

Authors:  M Binnebösel; P Bruners; C D Klink; C Kuhl; U P Neumann
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

6.  Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases.

Authors:  Moritz Koch; Peter Kienle; Ulf Hinz; Dalibor Antolovic; Jan Schmidt; Christian Herfarth; Magnus von Knebel Doeberitz; Jürgen Weitz
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

Review 7.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 8.  Surgery for colorectal liver metastases.

Authors:  J N Primrose
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  An overview of the surgical management of hepatic neuroendocrine metastases.

Authors:  S Pathak; I Dash; M R Taylor; G J Poston
Journal:  Indian J Surg Oncol       Date:  2012-02-16

10.  Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Authors:  Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.